Premium
Activation of Cascade‐Like Antitumor Immune Responses through In Situ Doxorubicin Stimulation and Blockade of Checkpoint Coinhibitory Receptor TIGIT (Adv. Healthcare Mater. 1/2022)
Author(s) -
Tian Tian,
Wang Jingguo,
Yin Fan,
Wu Miaomiao,
He Wei,
Wang Xuefu,
Zha Zhengbao,
Wang Hua
Publication year - 2022
Publication title -
advanced healthcare materials
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.288
H-Index - 90
eISSN - 2192-2659
pISSN - 2192-2640
DOI - 10.1002/adhm.202270006
Subject(s) - tigit , blockade , cancer research , immune system , effector , immune checkpoint , doxorubicin , pharmacology , immunology , medicine , immunotherapy , receptor , chemotherapy
Enzyme‐Responsive Drug Release In article number 2102080, Zhengbao Zha, Hua Wang, and co‐workers encapsulate chemotherapeutic DOX and aTIGIT drugs together in a gelatin‐based hydrogel to synergistically realize immunogenic tumors, which promote the infiltration of NK and effector T cells and then are further stimulated by the subsequently released aTIGIT, to boost multilayered innate and adaptive immune responses for durable and long‐lasting anti‐tumor therapy.